v3.26.1
Segment Reporting - Summary of Revenue Significant Expenses and Net Loss for Segment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Collaboration revenue $ 398 $ 1,534  
Research and development costs 18,411 43,766  
Impairment of property and equipment   1,883 $ 1,600
Impairment of right-of-use assets   22,836  
Restructuring and other related charges 1,469 10,896  
Total operating expenses 31,420 97,882  
Loss from operations (31,022) (96,348)  
Interest income 1,133 2,952  
Other income 981    
Total other income 2,114 2,952  
Loss before income tax expense (28,908) (93,396)  
Income tax expense (11) (39)  
Net loss (28,919) (93,435)  
Clinical Related Costs      
Segment Reporting Information [Line Items]      
Research and development costs 2,920 15,156  
Employee Related Costs      
Segment Reporting Information [Line Items]      
Research development general and administrative costs 10,557 22,828  
Product Development and Manufacturing Costs      
Segment Reporting Information [Line Items]      
Research and development costs 818 3,304  
Facilities, Support Costs and Depreciation      
Segment Reporting Information [Line Items]      
Research development general and administrative costs 10,718 13,579  
Professional, Consulting and Public Company Costs      
Segment Reporting Information [Line Items]      
Research development general and administrative costs $ 4,938 $ 7,400